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Test-retest analysis of a non-invasive
method of quantifying [11C]-PBR28 binding
in Alzheimer’s disease
Akshay Nair1*, Mattia Veronese2, Xiaohui Xu3,4, Charles Curtis3,4, Federico Turkheimer2, Robert Howard5
and Suzanne Reeves5
Abstract
Purpose: In order to maximise the utility of [11C]-PBR28 for use in longitudinal studies and clinical trials in Alzheimer’s
disease (AD), there is a need to develop non-invasive metrics of tracer binding that do not require arterial cannulation.
Recent work has suggested that standardised uptake value (SUV)-based methods may be sensitive to changes in
translocator protein (TSPO) levels associated with neurodegeneration. However, the test-retest reliability of these
approaches in AD over a time period relevant for clinical trials is unknown. In this study, the test-retest reliability
of three SUV-based metrics was assessed in AD patients over 12 weeks.
Methods: Five patients with mild AD and the high-affinity binding TSPO genotype underwent two [11C]-PBR28
PET scans approximately 12 weeks apart. The test-retest reliability (TRR) of the unadjusted SUV, SUV relative to
cerebellar grey matter (SUVRC) and SUV normalised to whole brain activity (SUVRWB) in nine cortical and limbic
regions of interest was assessed using the absolute variability and the intraclass correlation coefficient.
Results: Of the three measures, SUVRWB performed best overall, showing low absolute variability (mean −0.13 %,
SD 2.47 %) and high reliability (mean ICC = 0.83). Unadjusted SUV also performed well, with high reliability (ICC = 0.94)
but also high variability (mean −1.24 %, SD 7.28 %). By comparison, the SUVRC showed higher variability
(mean −3.98 %, SD 7.07 %) and low reliability (ICC = 0.65).
Conclusions: In this AD sample, we found that SUV-derived metrics of [11C]-PBR28 binding showed high
stability over 12 weeks. These results compare favourably with studies reporting TRR of absolute quantification of
[11C]-PBR28. Pending further validation of SUV-based measures of [11C]-PBR28, semi-quantitative methods of
[11C]-PBR28 analysis may prove useful in longitudinal studies of AD.
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Introduction
Activated microglia play an important role in the patho-
physiology of Alzheimer’s disease (AD) [1]. Positron emis-
sion tomography (PET), using radioligands that bind to
the mitochondrial 18 kDa translocator protein (TSPO), al-
lows in vivo quantification of microglia in their activated
state [2]. In comparisons with unaffected controls, TSPO
binding has been shown to be significantly higher in AD
and there has been interest in using second-generation
TSPO ligands, including [11C]-PBR28, in longitudinal
studies and clinical trials of immunomodulatory drugs [3].
Although [11C]-PBR28 is known to have a better
signal-to-noise ratio and pharmacokinetic properties,
compared to the first-generation TSPO tracer [11C]-R-
PK11195, its use in longitudinal studies of AD is limited
by several factors [4]. The absence of both a true refer-
ence region and an established pseudo-reference ap-
proach, such as the supervised clustering algorithm
developed for [11C]-R-PK11195, means that most studies
using [11C]-PBR28 require arterial cannulation [5]. This
procedure adds cost, is invasive and can be uncomfort-
able. This limits the use of [11C]-PBR28 in studies with
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repeated measures and in AD patients, for whom toler-
ability and informed consent are significant issues. As an
alternative to absolute quantification, three studies have
recently demonstrated that a semi-quantitative, non-
invasive approach using the standardised uptake value
(SUV) or SUV ratio (SUVR) may be sensitive to changes
in TSPO levels associated with neurodegenerative dis-
eases including AD [6–8]. Although the SUV/SUVR do
not provide details of compartmental binding, they are
easy to derive, do not require arterial sampling and can
reduce time spent in the scanner—appealing properties
for use in patients with dementia. For these approaches
to have utility for longitudinal studies, the test-retest re-
liability (TRR) needs to be established over a time period
meaningful in clinical trials. In this study, a TRR analysis
of the three published SUV-based methods for analysing
[11C]-PBR28 data was conducted in a cohort of AD
patients over a 12-week period.
Materials and methods
Patient recruitment
Participants were recruited from memory clinics in
South London and Maudsley NHS Foundation Mental
Health Trust. Inclusion and exclusion criteria were de-
signed to reflect those of an on-going clinical trial of
minocycline in patients with AD. Inclusion criteria in-
cluded (i) age 55–95 years, (ii) diagnosis meeting the
National Institute on Aging-Alzheimer’s Association
(NIA/AA) criteria of possible or probable AD, (iii) stan-
dardised mini-mental state examination (sMMSE) >/=23
and (iv) consenting to participate [9, 10]. Exclusion cri-
teria were (i) contraindication to administration of min-
ocycline, (ii) presence of a variant of a polymorphism in
the TSPO gene associated with low or medium tracer
binding, (iii) contraindications to receiving a MRI scan
and (vii) any medical conditions that might affect a per-
son’s ability to tolerate the PET scan procedure [11].
Fourteen patients were screened for the study, and nine
were excluded due to incompatible genotype. This study
was ethically approved by the South Central Berkshire
NRES Committee and was conducted according to the
Declaration of Helsinki. All subjects gave written in-
formed consent for participation.
PET imaging procedure
Participants were scanned twice with a mean inter-scan
time of 82 ± 10.2 days. Both scans were carried out on
the same Siemens PET/CT camera at the Imanova
Centre, London, and all patients were scanned at the
same time of the day on both visits. [11C]-PBR28 was
synthesised on site immediately prior to use according
to local guidelines and regulations. For detailed de-
scription of synthesis and quality control procedures,
please see Owen et al. (2014) [12]. [11C]-PBR28 was
given as an intravenous infusion over 20 s. There were
no significant differences between the doses injected at
each scan (test = 339.0 ± 4.6 Mbq, retest = 350.8 ±
14.2 Mbq, p = 0.154). Dynamic image data were collected
over 60 min and binned into 23 frames (durations: 8 ×
15 s, 3 × 1 min, 5 × 2 min, 5 × 5 min, 2 × 10 min). Images
were reconstructed using filtered back projection. A low-
dose CT head scan was acquired for each subject for scat-
ter and attenuation correction. Structural imaging
(1.5TT1-weighted MRI) was carried out to exclude intra-
cranial abnormalities and for co-registration.
Genotyping
The SNP rs6971 was genotyped using TaqMan® SNP
genotyping assays on a 7900HT sequence detection system
(Applied Biosystems) and analysed using SDS software.
Image analysis
Structural MRI scans were co-registered to PET images for
tissue segmentation and region of interest (ROI) definition.
A neuroanatomical atlas was co-registered onto each sub-
ject’s MRI data and PET image using a combination of Stat-
istical Parametric Mapping 8 (http://www.fil.ion.ucl.ac.uk/
spm) and FSL (http://www.fsl.fmrib.ox.ac.uk/fsl) functions,
as implemented in MIAKAT™ (http://www.miakat.org/).
The binding of [11C]-PBR28 in nine cortical and limbic
ROIs was evaluated after applying a grey matter mask (see
Table 1). These regions have previously been shown to be
associated with increased TSPO signal in AD [3]. For bilat-
eral regions, data from both hemispheres were analysed
separately and then combined. The final 20-min window of
the scan (40 to 60 min) was used to derive the SUV. Time-
stability analysis for this time window is shown in
Additional file 1. Unadjusted SUV in designated ROIs, SUV
normalised to the whole brain (SUVRWB) and normalised
to the cerebellum (SUVRC) were outcome measures, con-
sistent with findings from previous reports as discussed
above.
Statistical analysis
Test-retest reliability was determined by calculating the
absolute variability between ‘test’ and ‘retest’ scans and
intraclass correlation coefficient (ICC), using a two-way
mixed model for consistency (class 3,1) in SPSS version 21
(www.spss.com). The mean regional difference (MRD)
was calculated as follows: (Retest–Test/Test) * 100. The
absolute variability (VAR) was calculated as follows:
(2 * (Test–Retest))/(Test + Retest) * 100. Two-tailed sam-
ple size calculations required to detect a 5 and 10 %
change in MRD were performed in using G*Power 3 soft-
ware, with a power of 0.9 and probability of type I error of
0.05 using the SD of the MRD for each ROI.
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Results
Sample characteristics
Five patients with high-affinity binding (HAB) genotype
were included in the study (mean age 82.9 ± 4 years, four
were male). Mean MMSE was 25.6 ± 1.3, and all patients
were currently prescribed acetylcholinesterase inhibitors
(AChEi). There were no significant differences in age or
MMSE score between those included in the study and
those excluded by genotype (mean age = 80.3 years ±
7.7 years, MMSE score = 25.8 ± 1.8).
Test-retest analysis
The test-retest analysis of the three methods of SUV
analysis is presented below—unadjusted SUV, SUVRWB
and SUVRC.
Unadjusted SUV
The mean test-retest values, absolute variability and ICC
for unadjusted SUV values are presented in Table 1.
There was significant mean absolute variability (mean
−1.24 %, SD 7.28 %) across ROIs. However, unadjusted
SUV measurements were highly reliable as indicated by
the high ICC values (mean ICC 0.94). From these data, a
sample size of 26 would be required to detect a 5 %
within-subject change in MRD (averaged across all
ROIs), and a sample size of 8 would be required to de-
tect a 10 % change.
SUV relative to whole brain mean activity
The mean test-retest values, absolute variability and ICC
for SUVRWB are presented in Table 2. There was low ab-
solute variability (mean −0.13 %, SD 2.47 %) across
ROIs, and the SUVRWB was highly reliable (mean ICC
0.83). Consequently, a sample size of 7 would be re-
quired to detect a 5 % within-subject change in MRD
(averaged across all ROIs), and a sample size of 4 would
be required to detect a 10 % change.
SUV normalised to cerebellar activity
The mean test-retest values, absolute variability and ICC
for SUVRC are presented in Table 3. There was consid-
erable absolute variability (mean −3.98 %, SD 7.07 %)
and SUVRC showed poor reliability (mean ICC 0.65).
Overall, a sample size of 25 would be required to detect
a 5 % within-subject change in MRD (averaged across all
ROIs), and a sample size of 8 would be required to de-
tect a 10 % change. Of the three measures, the SUVRC
performed most poorly, due to high levels of variability
in binding in the cerebellar grey matter reference region.
Discussion
Of the three SUV measures present in this test-retest
analysis, the SUV normalised to whole brain mean activ-
ity performed most strongly. The unadjusted SUV
showed higher variability, and the SUVRC showed both
Table 1 Test-retest analysis of unadjusted SUV
Mean test value Mean retest Mean regional
difference % (SD)
Mean VAR % (SD)a ICC Sample size to detect
5 % changeb
Sample size to detect
10 % changeb
Frontal lobe 1.22 1.24 1.40
(6.62)
−1.22
(6.50)
0.96 21 7
Parietal lobe 1.17 1.19 2.33
(7.61)
−2.08
(7.49)
0.94 27 9
Temporal lobe 1.17 1.18 0.98
(7.34)
−0.76
(7.27)
0.93 25 8
Occipital lobe 1.21 1.22 0.87
(8.07)
−0.61
(8.10)
0.93 30 9
Hippocampus 1.06 1.08 2.01
(6.55)
−1.82
(6.48)
0.93 21 7
Parahippocampal cortex 1.15 1.18 2.91
(6.27)
−2.72
(6.08)
0.97 19 7
Posterior cingulate 1.31 1.35 3.27
(7.20)
−3.02
(7.03)
0.95 24 8
Amygdala 1.22 1.22 1.49
(6.01)
−1.34
(5.73)
0.98 18 7
Cerebellum 1.32 1.29 −1.81
(10.22)
2.28
(10.93)
0.87 45 14
Whole brain 1.13 1.14 1.35
(7.30)
−1.13
(7.22)
0.94 25 8
Mean
(SD)
1.20
(0.08)
1.21
(0.08)
1.48
(7.32)
−1.24
(7.28)
0.94 26 8
ICC intraclass correlation coefficient
aVAR = absolute variability (%)
bModel parameters: two-tailed, power 0.9, alpha 0.05
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higher temporal variability and lower reliability. Lower
reliability in SUVR methods, as measured by ICC, was
most apparent in smaller regions with lower signal to
noise ratios, such as the parahippocampal gyrus, which
is affected early in the AD process.
Compared to published data on the TRR of [11C]-
PBR28, the SUV methods presented here perform well
[13, 14]. Park et al. reported that, over a 1.4-week period,
in healthy controls and patients with multiple sclerosis,
the SDs of test-retest variability of VT and VT/fp (derived
Table 2 Test-retest analysis of SUV relative to whole brain mean activity (SUVRWB)
Mean test value Mean retest value Mean regional
difference % (SD)
Mean VAR% (SD)a ICC Sample size to detect
5 % changeb
Sample size to detect
10 % changeb
Frontal lobe 1.08 1.08 0.096
(1.42)
−0.09
(1.41)
0.96 4 3
Parietal lobe 1.03 1.04 0.96
(0.81)
−0.95
(0.80)
0.98 3 3
Temporal lobe 1.04 1.03 −0.36
(0.73)
0.37
(0.73)
0.90 3 3
Occipital lobe 1.07 1.06 −0.51
(1.35)
0.52
(1.37)
0.91 4 3
Hippocampus 0.94 0.95 0.71
(2.09)
−0.69
(2.06)
0.97 5 3
Parahippocampus 1.01 1.03 1.64
(3.07)
−1.59
(2.98)
0.48 7 4
Posterior cingulate 1.15 1.17 1.92
(1.36)
−1.89
(1.33)
0.98 4 3
Amygdala 1.07 1.07 0.35
(5.79)
−0.21
(5.77)
0.69 17 6
Cerebellum 1.17 1.13 −3.24
(5.40)
3.42
(5.74)
0.63 15 6
Mean
(SD)
1.06
(0.07)
1.06
(0.06)
0.17
(2.45)
−0.13
(2.47)
0.83 7 4
ICC intraclass correlation coefficient
aVAR = absolute variability (%)
bModel parameters: two-tailed, power 0.9, alpha 0.05
Table 3 Test-retest analysis of SUV relative to cerebellar activity (SUVRC)
Mean Test Value Mean Retest Value Mean regional
difference % (SD)
Mean VAR % (SD)a ICC Sample size to detect
5 % changeb
Sample size to detect
10 % changeb
Frontal lobe 0.93 0.96 3.78
(7.63)
−3.50
(7.06)
0.69 27 9
Parietal lobe 0.89 0.93 4.62
(6.37)
−4.37
(5.94)
0.70 20 7
Temporal lobe 0.89 0.92 3.23
(5.87)
−3.05
(5.22)
0.68 17 6
Occipital lobe 0.92 0.94 3.04
(4.98)
−2.90
(4.75)
0.71 13 5
Hippocampus 0.81 0.84 4.44
(8.18)
−4.11
(7.54)
0.77 31 10
Parahippocampus 0.87 0.92 5.46
(9.51)
−5.00
(8.59)
0.38 40 12
Posterior cingulate 0.99 1.05 5.65
(7.25)
−5.31
(6.65)
0.79 25 8
Amygdala 0.92 0.95 4.18
(11.53)
−3.62
(10.51)
0.47 25 8
Mean (SD) 0.90
(0.05)
0.94
(0.06)
4.30
(7.66)
−3.98
(7.07)
0.65 25 8
ICC intraclass correlation coefficient
aVAR = absolute variability (%)
bModel parameters: two tailed, power 0.9, alpha 0.05
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using a multi-linear analysis) varied from 9 to 11 % and
7 to 14 %, respectively [13]. Collste et al. [14] reported
that the mean absolute variability in VT in the grey mat-
ter was 18.3 ± 12.7 %, with ICC values from 0.90 to 0.94,
and that, using a parametric modelling approach,
variability was 17.8 ± 12.7 %. Participants were imaged
either on the same day or 1 day apart. By comparison,
all three SUV measures in our study performed well,
over a much longer time period. These results also com-
pare favourably with TRR analysis of the first-generation
TSPO ligand [11C]-R-PK11195 [5, 15].
These findings should be viewed as a preliminary indica-
tor that SUV-based methods may be suitable for use in
longitudinal studies in AD. Our findings should be con-
firmed in larger samples, which could also include
medium-affinity binders to assess the impact of genotype
on longitudinal variability. Further work is also needed to
confirm the relationship between SUV measures and mea-
sures of specific binding. Although there are concerns
about the non-specific binding profile of [11C]-PBR28,
work by Lyoo et al. suggests that SUVRC correlates well
with absolute quantification, but more data on this is re-
quired [8, 16]. This validation is also required for alterna-
tive SUV-derived methods, and this could be easily
achieved through retrospective analysis of existing data
sets. Although SUV and SUVRWB appear to have better
test-retest reliability, other factors such as sensitivity to
disease states may vary between methods and should be
considered when choosing a quantification method.
In conclusion, given the caveats listed above, this TRR
analysis of SUV-derived measures of [11C]-PBR28 bind-
ing in AD suggests that non-invasive semi-quantitative
approaches are stable and reliable over significant pe-
riods of time.
Additional file
Additional file 1: Time-stability analysis for 40-60 mins time window.
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